INmune Bio Inc. (NasdaqCM: INMB)
Health Care · Biotechnology · US
$1.46
-4.58% today · -18.4% 1Y
INmune Bio Inc. (NasdaqCM: INMB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $40.52M and employs 21 people.
Over the last twelve months the share price has lost 18.4%, trading between 1.09 and 2.60.
Tweenvest scores INmune Bio Inc. across four factors: quality 37/100, value 34/100, growth 100/100. Its strongest factor is growth.
INMB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $40.52M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.69
- Dividend yield
- —
- Beta (5Y)
- 0.90
- 52-week high
- $2.60
- 52-week low
- $1.09
- Avg volume (3M)
- —
- Shares outstanding
- 27.75M
- Employees
- 21
- Next earnings
- —
About INmune Bio Inc.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
- ISIN
- US45782T1051
- Founded
- 2015
- Listed since
- Feb 4, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biomolecular Life Holdings, Inc.OTCPK: BIOM | $41.44M | $0.81 | -18.18% |
| KoBioLabs, IncKOSDAQ: A348150 | $40.93M | ₩2,810.00 | -2.43% |
| Cutia TherapeuticsSEHK: 2487 | $40.89M | HK$0.86 | +0.58% |
| NurExone Biologic Inc.TSXV: NRX | $40.89M | CA$0.60 | -3.33% |
| TegoScience Inc.KOSDAQ: A191420 | $40.24M | ₩6,700.00 | -5.63% |
| Instil Bio, Inc.NasdaqCM: TIL | $40.08M | $5.91 | -12.31% |
| Genomics BioSci & Tech. Co.,Ltd.TWSE: 4195 | $38.71M | NT$15.70 | -3.68% |
| ME Therapeutics Holdings Inc.CNSX: METX | $38.53M | CA$1.80 | -35.71% |
Figures last refreshed Oct 18, 2026.